Skip to main content
Premium Trial:

Request an Annual Quote

Gen-Probe Shares Close Down on WSJ Report

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Shares of Gen-Probe fell more than 2 percent in Tuesday trade after a report in The Wall Street Journal said that Novartis was no longer "actively pursuing" a deal to acquire the San Diego-based molecular diagnostics firm.

Novartis was believed to be the sole remaining bidder for Gen-Probe after Life Technologies and Thermo Fisher Scientific reportedly backed out of the bidding process.

News that Gen-Probe was for sale first emerged in late April, after the firm had reportedly hired Morgan Stanley to seek a buyer. In addition to the firms already mentioned, Danaher was initially listed as a potential buyer.

Last week, investment firm Canaccord Genuity cut its price target on Gen-Probe's stock to $75 from $88, saying that there appeared to be no competitive bids to acquire the molecular diagnostics firm.

Gen-Probe's shares closed at $62.41 in Tuesday trade on the Nasdaq. Its shares had not traded that low since early March.

In a research note published Tuesday afternoon, Baird Analyst Quintin Lai said that despite the drop, "we believe there has been no change in [Gen-Probe's] fundamental business and pipeline."

Lai followed that note with another on Wednesday morning, upgrading the firm's stock rating to Outperform with a $75 price target, down from a previous target of $82.

Jefferies Analyst Jon Wood also lowered the price target on Gen-Probe to $75 from a previous $92. Wood said that it is "inconceivable" that "a well-capitalized and entrenched molecular diagnostic franchise would be unable to attract a healthy premium in current market conditions."

The Scan

Booster for Kids

The US Food and Drug Administration has authorized a booster dose of Pfizer-BioNTech's SARS-CoV-2 vaccine for 5-to-11-year olds, the Washington Post reports.

Novavax Anticipates Authorization

Novavax expects to receive US Food and Drug Administration authorization for vaccine soon, according to CNBC.

Some Old Microbes Indeed

Vice reports that researchers may have uncovered 830-million-year-old microbes.

PNAS Papers on Meiotic Crossover, RNA Targeting, SNAT7 mTORC1 Regulation

In PNAS this week: meiotic crossover formation in C. elegans, approach to identify small molecules affecting RNA activity, and more.